Skip to content
Peptigraph home

Sermorelin vs BPC-157: What the Research Shows

Sermorelin and BPC-157 side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH analogCompounded by prescriptionSermorelinGHRH analog once FDA-approved as Geref and since discontinued; in an uncontrolled pediatric study mean height velocity rose from 4.1 to 8.0 cm/yr after 6 months.[18]Growth hormoneFlat YoYGastric pentadecapeptidePCAC voted 8–6 for 503A (Jul 2026)BPC-157BPC-157, an experimental gastric pentadecapeptide, not an approved drug; human evidence is a few small uncontrolled reports, including complete symptom resolution in 10 of 12 patients in a bladder pilot.[15]Healing & recoveryMost searched
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider Sermorelin if…

  • you want human data in growth-hormone-deficient children, though uncontrolled: Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months (open-label, no control group).[18]

Consider BPC-157 if…

  • you want any human reports (a small, uncontrolled report): 14 of 16 patients (87.5%) reported relief with BPC 157 alone or combined with thymosin beta-4 (TB4).[19]

What they have in common

  • Caution on BPC-157 evidence from a systematic review: Only 1 of 36 included studies was clinical; 35 were preclinical.[20]
Neither is FDA approved for any use in people. Both are prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 13 of 13 fields where the two differ.

FieldSermorelinBPC-157
ClassGHRH analogGastric pentadecapeptide
Also called—BPC, body protection compound, Pentadecapeptide BPC 157
CategoryGrowth hormoneHealing & recovery
FDA statusCompounded by prescriptionPCAC voted 8–6 for 503A (Jul 2026)
PCAC vote, Jul 2026Not on the Jul 2026 agendaPCAC voted 8–6 for the 503A list (Jul 2026); not finalized
WADAProhibited by WADA (S2.2.4)Sermorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times.Prohibited by WADA (S0)BPC-157 is named in S0 (non-approved substances), prohibited at all times, in and out of competition.
Anti-doping detection
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
  • A 2023 method detects BPC-157 and five main metabolites in human urine at very low concentrations.PMID 37959764
  • A 2017 anti-doping lab method detects BPC 157 in urine; the peptide was stable in urine for at least 4 days.PMID 28035768
Half-lifeNo published half-life foundPubMed search, 2 Oct 2026less than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 36588717
Evidence strengthHuman RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 1992, PMID 1379256Human observational evidence, 3 of 4Strongest: Alternative therapies in health and medicine 2025, PMID 40131143
Human studies we summarised4 human (1 randomized or controlled) of 7 summarised3 human (0 randomized or controlled) of 24 summarised
Typical study doses
Vial sizes sold2 mg, 5 mg, 9 mg, 15 mg2 mg, 5 mg, 10 mg, 20 mg
US searches per month165,000 · Flat YoY301,000 · Most searched

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Taken together?

Sermorelin and BPC-157 together

People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 2 results, 2 Oct 2026).

Open the stack page
StackSermorelin + BPC-157, taken as separate injectionsStack page

Sources

  1. 1FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  4. 4Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  5. 5Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
  6. 6Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
  7. 7Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
  8. 8PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.Molecules (Basel, Switzerland) · 2023PMID 37959764Accessed 2 Oct 2026
  12. 12Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.Drug testing and analysis · 2017PMID 28035768Accessed 2 Oct 2026
  13. 13Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
  14. 14Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.Alternative therapies in health and medicine · 2025PMID 40131143Accessed 2 Oct 2026
  15. 15Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.Alternative therapies in health and medicine · 2024PMID 39325560Accessed 2 Oct 2026
  16. 16Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
  17. 17PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (sermorelin[tiab] OR Geref[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  18. 18Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
  19. 19Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.Alternative therapies in health and medicine · 2021PMID 34324435Accessed 2 Oct 2026
  20. 20Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025PMID 40756949Accessed 2 Oct 2026
  21. 21Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org

Found an error? Report a correction.